Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...
$ 84.38-0.07-0.08% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback